ResearcherUniversity Hospital in HalleActive in the last 2 years
Yijun Chen
Matched on ORCID iD 0000-0001-7020-4517; OpenAlex author ID A5100413911. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 3
2022: 1 paper · 2023: none · 2024: 2 papers
Papers 3
- Periostin is associated with prognosis and immune cell infiltration in pancreatic adenocarcinoma based on integrated bioinformatics analysis. Co-author DOI 10.1002/cnr2.1990↗
- Pancreatic cancer cell- and cancer-associated fibroblast-derived exosomes in disease progression, metastasis, and therapy. Co-author DOI 10.1007/s12672-024-01111-z↗
- Single Cell Analysis of Cultivated Fibroblasts from Chronic Pancreatitis and Pancreatic Cancer Patients. First author DOI 10.3390/cells11162583↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yoshiaki Sunami · 3 shared papers, 2022–2024 · strength 0.78
- Paper Pancreatic cancer cell- and cancer-associated fibroblast-derived exosomes in disease progression, metastasis, and thera… DOI 10.1007/s12672-024-01111-z↗
- Paper Periostin is associated with prognosis and immune cell infiltration in pancreatic adenocarcinoma based on integrated bi… DOI 10.1002/cnr2.1990↗
- Paper Single Cell Analysis of Cultivated Fibroblasts from Chronic Pancreatitis and Pancreatic Cancer Patients. DOI 10.3390/cells11162583↗
- Jorg H. Kleeff · 3 shared papers, 2022–2024 · strength 0.78
- Paper Pancreatic cancer cell- and cancer-associated fibroblast-derived exosomes in disease progression, metastasis, and thera… DOI 10.1007/s12672-024-01111-z↗
- Paper Periostin is associated with prognosis and immune cell infiltration in pancreatic adenocarcinoma based on integrated bi… DOI 10.1002/cnr2.1990↗
- Paper Single Cell Analysis of Cultivated Fibroblasts from Chronic Pancreatitis and Pancreatic Cancer Patients. DOI 10.3390/cells11162583↗
- Monika Hämmerle · 2 shared papers, 2022–2024 · strength 0.41
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.